Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Interest & Investment Income (2021 - 2025)

Amylyx Pharmaceuticals (AMLX) has 5 years of Interest & Investment Income data on record, last reported at $3.3 million in Q4 2025.

  • For Q4 2025, Interest & Investment Income rose 42.06% year-over-year to $3.3 million; the TTM value through Dec 2025 reached $9.3 million, down 32.64%, while the annual FY2025 figure was $9.3 million, 32.64% down from the prior year.
  • Interest & Investment Income reached $3.3 million in Q4 2025 per AMLX's latest filing, up from $1.8 million in the prior quarter.
  • Across five years, Interest & Investment Income topped out at $4.4 million in Q4 2023 and bottomed at $1000.0 in Q2 2021.
  • Average Interest & Investment Income over 5 years is $2.2 million, with a median of $2.3 million recorded in 2024.
  • Peak YoY movement for Interest & Investment Income: skyrocketed 40100.0% in 2022, then tumbled 51.83% in 2025.
  • A 5-year view of Interest & Investment Income shows it stood at $30000.0 in 2021, then skyrocketed by 10423.33% to $3.2 million in 2022, then soared by 38.45% to $4.4 million in 2023, then crashed by 47.01% to $2.3 million in 2024, then skyrocketed by 42.06% to $3.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Interest & Investment Income were $3.3 million in Q4 2025, $1.8 million in Q3 2025, and $2.0 million in Q2 2025.